Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Department of Pharmaceutical Sciences, Vancouver General Hospital, and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Can J Anaesth. 2020 Dec;67(12):1798-1805. doi: 10.1007/s12630-020-01814-1. Epub 2020 Sep 16.
Sepsis has high incidence and mortality rates, particularly in the intensive care unit (ICU). Corticosteroids may improve outcomes, and vitamin C may add benefit. We aimed to assess whether vitamin C and corticosteroids improved outcomes compared with corticosteroids alone.
This historical cohort study (11 December 2016 to 21 February 2018) was conducted in the ICU of a quaternary referral hospital. Patients with an ICU admission diagnosis of sepsis or septic shock who received vitamin C and hydrocortisone within 72 hr were compared with those who received only hydrocortisone. All patients received standard sepsis care including source control, antibiotics, and fluid resuscitation. Most patients received thiamine as standard ICU care. The primary outcome was hospital mortality. Secondary outcomes included ICU mortality, ventilator-free days, vasopressor-free days, dialysis use, and duration of ICU admission.
One hundred and forty-four patients were included in the study. The mean (standard deviation [SD]) age was 64 (15) yr; 39% were female; and the mean (SD) Acute Physiology And Chronic Health Evaluation IV score was 89 (30). Eighty-eight patients did not receive vitamin C and 52 received vitamin C. There was no observed difference in hospital mortality between the non-vitamin C (36%) and vitamin C (39%) groups (adjusted odds ratio for hospital death, 0.52; 95% confidence interval, 0.20 to 1.34; P = 0.18). There were no statistically significant differences in any secondary outcomes.
In this small observational study of ICU patients with septic shock, the addition of vitamin C to hydrocortisone therapy did significantly affect hospital mortality or other measures of mortality or organ dysfunction.
脓毒症发病率和死亡率较高,尤其是在重症监护病房(ICU)。皮质类固醇可能改善预后,维生素 C 可能会带来额外益处。我们旨在评估维生素 C 和皮质类固醇联合治疗是否优于单独使用皮质类固醇。
这是一项历史队列研究(2016 年 12 月 11 日至 2018 年 2 月 21 日),在一家四级转诊医院的 ICU 进行。在 72 小时内接受维生素 C 和氢化可的松治疗的 ICU 入院诊断为脓毒症或脓毒性休克的患者与仅接受氢化可的松治疗的患者进行比较。所有患者均接受标准脓毒症治疗,包括源头控制、抗生素和液体复苏。大多数患者接受硫胺素作为标准 ICU 护理。主要结局为医院死亡率。次要结局包括 ICU 死亡率、无呼吸机天数、无血管加压素天数、透析使用和 ICU 入住时间。
本研究共纳入 144 例患者。患者的平均(标准差)年龄为 64(15)岁;39%为女性;急性生理学和慢性健康评估 IV 评分的平均值(标准差)为 89(30)。88 例患者未接受维生素 C,52 例患者接受了维生素 C。未接受维生素 C 组(36%)和接受维生素 C 组(39%)的医院死亡率无显著差异(医院死亡的校正优势比,0.52;95%置信区间,0.20 至 1.34;P=0.18)。其他次要结局也无统计学差异。
在这项 ICU 脓毒性休克患者的小型观察性研究中,氢化可的松治疗中添加维生素 C 并未显著影响医院死亡率或其他死亡率或器官功能障碍的衡量标准。